Healthcare / Medical DevicesParis
$0.72
-0.03 (-4.53%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-3.0M · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$52M
P/E
N/A
•EV/EBITDA
N/A
•ROE
5050100.9%
↑Gross Margin
-346.0%
↓Debt/Equity
-11369.81
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-17.5%
FCF CAGR
—
FCF margin
-362.9%
FCF / Net income
0.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $830209.0 · net income $-5.8M · FCF $-3.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $830209.00 | $830209.00 | $1.8M | $1.2M | $1.5M |
| Net Income | $-5.8M | $-5.8M | $-3.7M | $-5.0M | $-3.8M |
| EBITDA | $-5.9M | $-5.9M | $-2.1M | $-5.7M | $-5.3M |
| EPS | -0.12 | -0.12 | -0.08 | -0.17 | — |
| Gross Margin | -346.0% | -346.0% | -59.3% | -246.9% | -154.2% |
| Operating Margin | -819.6% | -819.6% | -172.2% | -507.7% | -356.5% |
| Net Margin | -693.5% | -693.5% | -201.7% | -401.8% | -253.9% |
| Balance Sheet | |||||
| Debt/Equity | -11369.81 | -11369.81 | 0.35 | 4.61 | -2.31 |
| Current Ratio | 2.79 | 2.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.0M | $-3.0M | $-2.6M | $-5.6M | $-4.0M |
| Returns | |||||
| ROE | 5050100.9% | 5050100.9% | -65.1% | -911.1% | 295.5% |
| Valuation | |||||
| P/B | — | — | 3.08 | 51.00 | — |
| Growth & Yield | |||||
| Revenue Growth | -54.4% | -54.4% | 47.5% | -16.6% | — |
| EPS Growth | -54.7% | -54.7% | 52.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+150.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → -0.12
Residual
+150.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.